相关实验视频

Updated: May 14, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

在患有复发性复发性多发性硬化症的患者中,ocrelizumab与rituximab的有效性

Nesma Mounir¹, Nevin Shalaby², Mohamed I Hegazy²

¹Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt. nesma.mounir@kasralainy.edu.eg.

Acta neurologica Belgica

|April 11, 2025

概括

在治疗复发性复发性硬化症 (RRMS) 中,ocrelizumab和rituximab的疗效相似. 这两种抗CD20单克隆抗体在该患者队列中的残疾恶化,复发率和残疾改善方面表现相似.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

奥克雷利祖马布 (OCR) 和利图西马布 (RTX) 是用于治疗多发性硬化症 (MS) 的CD20向单克隆抗体.
虽然这两种药物都会耗尽B细胞,但对MS患者的直接比较疗效研究 (pwMS) 是有限的.
本研究解决了在RRMS管理中对OCR和RTX有效性进行比较的持续需求.

研究的目的:

为了比较ocrelizumab与rituximab在复发性复发性多发性硬化症 (RRMS) 患者的临床疗效.
评估OCR和RTX治疗组之间的残疾进展,复发率和康复的差异.

主要方法:

在一个单个研究单位对126名RRMS患者进行了OCR或RTX治疗的回顾性队列研究.
输注后至少一年收集的数据.
主要结局:时间到3个月确认残疾恶化 (CDW). 二次结局包括第一次复发的时间 (TTFR),3个月确认的残疾改善 (CDI),年复发率 (ARR) 和MRI活动.

主要成果:

在OCR和RTX组之间没有观察到CDW率的显著差异 (9.37%对11.29%).
发现了可比的3个月确认残疾改善率 (CDI) 和年均复发率 (ARR).
在两个治疗组之间,在第一次复发的时间 (TTFR) 或时间到3个月的CDW之间没有显著的差异.

结论:

在治疗复发性复发性多发性硬化症方面,ocrelizumab和rituximab的疗效相似.
该研究表明,对于RRMS患者来说,这两种抗CD20疗法在关键临床结果中没有显著差异.

关键词:

有效性有效性.多发性硬化症是多发性硬化症.这就是Ocrelizumab.里图西马布 (Rituximab) 是一种药物.

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

相关概念视频

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.